These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and EBM]. Toba A; Kuwajima I Clin Calcium; 2010 Jan; 20(1):9-15. PubMed ID: 20048428 [TBL] [Abstract][Full Text] [Related]
25. Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use. Silvestry FE; St John Sutton MG Eur Heart J; 1998 Aug; 19 Suppl I():I8-14. PubMed ID: 9743438 [TBL] [Abstract][Full Text] [Related]
26. [Calcium antagonists: current and future applications based on new evidence. Renal protective action of calcium channel blockers]. Kimura G Clin Calcium; 2010 Jan; 20(1):94-9. PubMed ID: 20048440 [TBL] [Abstract][Full Text] [Related]
27. Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis. Survase S; Ivey ME; Nigro J; Osman N; Little PJ Vasc Health Risk Manag; 2005; 1(3):199-208. PubMed ID: 17319105 [TBL] [Abstract][Full Text] [Related]
28. Antioxidants in hypertension and cardiovascular disease. Schiffrin EL Mol Interv; 2010 Dec; 10(6):354-62. PubMed ID: 21263161 [TBL] [Abstract][Full Text] [Related]
29. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Toba H; Nakagawa Y; Miki S; Shimizu T; Yoshimura A; Inoue R; Asayama J; Kobara M; Nakata T Hypertens Res; 2005 Aug; 28(8):689-700. PubMed ID: 16392774 [TBL] [Abstract][Full Text] [Related]
30. Fundamentals of calcium channel blockers. Das G Int J Clin Pharmacol Ther Toxicol; 1988 Dec; 26(12):575-84. PubMed ID: 3061939 [TBL] [Abstract][Full Text] [Related]
31. [Differential therapy with calcium antagonists]. Scholze JE Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111 [TBL] [Abstract][Full Text] [Related]
33. Application of calcium channel blockers in the treatment of cardiovascular diseases. Herman ZS Pol J Pharmacol; 1999; 51(2):201-6. PubMed ID: 10425650 [TBL] [Abstract][Full Text] [Related]
34. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Godfraind T Philos Trans R Soc Lond B Biol Sci; 2005 Dec; 360(1464):2259-72. PubMed ID: 16321796 [TBL] [Abstract][Full Text] [Related]
35. Calcium channel blockers in treatment of hypertension. Muntwyler J; Follath F Prog Cardiovasc Dis; 2001; 44(3):207-16. PubMed ID: 11727278 [TBL] [Abstract][Full Text] [Related]
37. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Yoshii T; Iwai M; Li Z; Chen R; Ide A; Fukunaga S; Oshita A; Mogi M; Higaki J; Horiuchi M Hypertens Res; 2006 Jun; 29(6):457-66. PubMed ID: 16940709 [TBL] [Abstract][Full Text] [Related]
38. Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. Hasegawa H; Takano H; Kohro T; Ueda K; Niitsuma Y; Aburatani H; Komuro I Hypertens Res; 2006 Sep; 29(9):719-29. PubMed ID: 17249528 [TBL] [Abstract][Full Text] [Related]